These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10418922)

  • 21. Cytotoxic T lymphocyte response against multiple simian immunodeficiency virusA (SIV) proteins in SIV-infected macaques.
    Venet A; Bourgault I; Aubertin AM; Kiény MP; Levy JP
    J Immunol; 1992 May; 148(9):2899-908. PubMed ID: 1349322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques.
    De Rose R; Batten CJ; Smith MZ; Fernandez CS; Peut V; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Venturi V; Davenport MP; Kent SJ
    J Virol; 2007 Jan; 81(1):292-300. PubMed ID: 17050602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.
    Maggiorella MT; Baroncelli S; Michelini Z; Fanales-Belasio E; Moretti S; Sernicola L; Cara A; Negri DR; Buttò S; Fiorelli V; Tripiciano A; Scoglio A; Caputo A; Borsetti A; Ridolfi B; Bona R; ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Ciccozzi M; Heeney J; Titti F; Cafaro A; Ensoli B
    Vaccine; 2004 Sep; 22(25-26):3258-69. PubMed ID: 15308348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytotoxic T-lymphocyte escape monitoring in simian immunodeficiency virus vaccine challenge studies.
    O'Connor DH; Allen TM; Watkins DI
    DNA Cell Biol; 2002 Sep; 21(9):659-64. PubMed ID: 12396608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.
    Cafaro A; Caputo A; Fracasso C; Maggiorella MT; Goletti D; Baroncelli S; Pace M; Sernicola L; Koanga-Mogtomo ML; Betti M; Borsetti A; Belli R; Akerblom L; Corrias F; Buttò S; Heeney J; Verani P; Titti F; Ensoli B
    Nat Med; 1999 Jun; 5(6):643-50. PubMed ID: 10371502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
    Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
    Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 Tat protein as a potential AIDS vaccine.
    Goldstein G
    Nat Med; 1996 Sep; 2(9):960-4. PubMed ID: 8782444
    [No Abstract]   [Full Text] [Related]  

  • 28. Cytotoxic T-lymphocyte induction in asymptomatic HIV-1-infected patients immunized with Retrovector-transduced autologous fibroblasts expressing HIV-1IIIB Env/Rev proteins.
    Ziegner UH; Peters G; Jolly DJ; Mento SJ; Galpin J; Prussak CE; Barber JR; Hartnett DE; Bohart C; Klump W
    AIDS; 1995 Jan; 9(1):43-50. PubMed ID: 7893440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retroviral vectors for HIV immunotherapy.
    Warner JF; Jolly D; Mento S; Galpin J; Haubrich R; Merritt J
    Ann N Y Acad Sci; 1995 Nov; 772():105-16. PubMed ID: 8546383
    [No Abstract]   [Full Text] [Related]  

  • 30. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins.
    Laube LS; Burrascano M; Dejesus CE; Howard BD; Johnson MA; Lee WT; Lynn AE; Peters G; Ronlov GS; Townsend KS
    Hum Gene Ther; 1994 Jul; 5(7):853-62. PubMed ID: 7981310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tat and Rev: positive modulators of human immunodeficiency virus gene expression.
    Rosen CA
    Gene Expr; 1991 May; 1(2):85-90. PubMed ID: 1820213
    [No Abstract]   [Full Text] [Related]  

  • 33. New finding on immune response to HIV Tat may contribute to vaccine, treatment.
    James JS
    AIDS Treat News; 2000 Sep; (351):4. PubMed ID: 12173551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune responses to SIVmne envelope glycoproteins protect macaques from homologous SIV infection.
    Hu SL; Travis BM; Stallard V; Abrams K; Misher L; Moran P; Zarling JM; Langlois AJ; Kuller L; Morton WR
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1489-94. PubMed ID: 1466988
    [No Abstract]   [Full Text] [Related]  

  • 35. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.
    Watkins JD; Lancelot S; Campbell GR; Esquieu D; de Mareuil J; Opi S; Annappa S; Salles JP; Loret EP
    Retrovirology; 2006 Jan; 3():8. PubMed ID: 16441880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Development of HIV-based retrovirus vector].
    Hayashi T; Okamoto T
    Nihon Rinsho; 1993 Sep; 51 Suppl():615-20. PubMed ID: 8271447
    [No Abstract]   [Full Text] [Related]  

  • 38. A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies.
    Krohn K; Stanescu I; Blazevic V; Vesikari T; Ranki A; Ustav M
    Microbes Infect; 2005 Nov; 7(14):1405-13. PubMed ID: 16257560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The rationale behind a vaccine based on multiple HIV antigens.
    Rollman E; Bråve A; Boberg A; Gudmundsdotter L; Engström G; Isaguliants M; Ljungberg K; Lundgren B; Blomberg P; Hinkula J; Hejdeman B; Sandström E; Liu M; Wahren B
    Microbes Infect; 2005 Nov; 7(14):1414-23. PubMed ID: 16257558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants.
    Zhao J; Lou Y; Pinczewski J; Malkevitch N; Aldrich K; Kalyanaraman VS; Venzon D; Peng B; Patterson LJ; Edghill-Smith Y; Woodward R; Pavlakis GN; Robert-Guroff M
    Vaccine; 2003 Sep; 21(25-26):4022-35. PubMed ID: 12922139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.